Koga Monji, Koga Kaori, Nakayama Juichiro
Department of Dermatology, Faculty of Medicine, Fukuoka, Japan.
Case Rep Dermatol. 2012 May;4(2):170-3. doi: 10.1159/000341946. Epub 2012 Aug 9.
Pityriasis rubra pilaris (PRP) is a rare chronic inflammatory keratosis that is clinically characterized by gradually developing reddish or orange extending plaques and keratotic follicular papules. In pediatric patients, we frequently hesitate to administer certain medications for treatment of PRP, specifically etretinate, systemic corticosteroids, and biologics recommended by previous studies. Although administration of high-dose vitamin A was described in a previous textbook of dermatology, details about the lower limits and treatment periods were not provided. We presented a pediatric case of PRP that was successfully controlled with minimum dosage of systemic vitamin A in the literature. Before and 14 days after beginning the therapy, both vitamin A levels of peripheral blood were within the normal range. We considered that the clinical efficacy may not be due to a supplementary effect of vitamin A, but to a pharmacological action because serum vitamin A was within the normal limits during the therapy.
红皮病型毛发红糠疹（PRP）是一种罕见的慢性炎症性角化病，其临床特征为逐渐出现的红色或橙色扩展斑块及角化性毛囊丘疹。在儿科患者中，我们常常对某些用于治疗PRP的药物，特别是阿维A、全身性皮质类固醇以及先前研究推荐的生物制剂的使用犹豫不决。尽管在先前的皮肤病学教科书中描述了高剂量维生素A的使用，但未提供下限及治疗周期的详细信息。我们在文献中呈现了一例儿科PRP病例，该病例通过最低剂量的全身性维生素A成功得到控制。在开始治疗前及治疗14天后，外周血维生素A水平均在正常范围内。我们认为临床疗效可能并非归因于维生素A的补充作用，而是由于药理作用，因为治疗期间血清维生素A处于正常范围。
